Evidence map›Paper›PMID 42762354›Full record

ReviewHuman genetics2026

Polygenic risk scores in human genetics for study design discovery and translation.

Hui-Qi Qu, Hakon Hakonarson

Abstract readReview
In one paragraph

Review in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hui-Qi QuThe Center for Applied Genomics, Children's Hospital of Philadelphia, 3615 Civic Center Blvd, Abramson Building, Philadelphia, PA, 19104, USA.
Hakon HakonarsonThe Center for Applied Genomics, Children's Hospital of Philadelphia, 3615 Civic Center Blvd, Abramson Building, Philadelphia, PA, 19104, USA. hakonarson@chop.edu.

Funding

Utilizing Polygenic Risk to Understand and Improve Outcomes: A Model For Overturning Health Disparities Through Minority-Enriched Genomics HealthcareU01HG011175 · NHGRI · CHILDREN'S HOSP OF PHILADELPHIA · PI Hakon Hakonarson · 2020 to 2026
$10.3M
National Human Genome Research Institute (NHGRI) U01HG011175NHGRI NIH HHS U01 HG011175
6 · The paper itself

Abstract

Polygenic risk scores (PRS) quantify the component of disease risk captured by measured additive common variants. Their use as a study design variable, rather than only as a predictive endpoint, broadens their scientific value in human genetics. PRS can define informative extremes of common-variant burden, identify discordance between phenotype and PRS-estimated risk, and facilitate the detection of subgroup-specific or residual mechanisms that may be obscured in conventional case-control analyses. This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype analysis of the component of phenotype remaining after the PRS-associated component has been removed. It thus provides a practical framework for sample enrichment, subgroup definition, and calibrated epidemiologic comparison. These designs may be especially informative when integrated with sequencing, multi-omics, longitudinal cohorts, and translationally oriented intervention studies. Their application requires careful attention to data leakage, ancestry-related bias, collider structures, and the limits of interpretation.

Indexed as

Genetic Predisposition to DiseaseHuman GeneticsMultifactorial InheritanceGenetic Risk ScoreGenome-Wide Association StudyHumansPhenotypeResearch Design

Identifiers

PMID42762354
PMCPMC13589714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.